On May 29, 2023 Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, reported a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held 2-6 June, 2023 in Chicago (Press release, Hummingbird Bioscience, MAY 29, 2023, View Source [SID1234632183]). The poster will summarize the Phase 1 clinical trial design for HMBD-002 (NCT05082610).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster describes the Phase 1, open-label, multi-center, first-in-human trial evaluating HMBD-002 as a monotherapy and in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). The study will be conducted under a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA. Monotherapy escalation cohorts 1-4 have been completed without dose-limiting toxicities, and the trial is currently enrolling cohort 5. Combination escalation is projected to begin in the second half of 2023.

"VISTA’s complex biology makes it a hard-to-drug target, yet we have shown in our preclinical studies that HMBD-002 has potent anti-tumor activity with its unique mechanism of action. In this poster at ASCO (Free ASCO Whitepaper), we will display the progress that HMBD-002 has made in Phase 1 trials," said Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience’s Chief Scientific Officer. "We look forward to discussing longer-term clinical development plans and combination strategies with the wider immuno-oncology community at ASCO (Free ASCO Whitepaper)."

ASCO Trials In Progress Poster Details:

Poster Title: A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors
Poster Session Track: Developmental Therapeutics—Immunotherapy
Poster Session Date: June 3, 2023
Time: 8:00 AM – 11:00 AM CDT
Location: Hall A
Poster Board Number: 505b
KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.